1. Home
  2. NGNE vs CIX Comparison

NGNE vs CIX Comparison

Compare NGNE & CIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.59

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo CompX International Inc.

CIX

CompX International Inc.

HOLD

Current Price

$21.60

Market Cap

296.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
CIX
Founded
2003
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
296.5M
IPO Year
N/A
1998

Fundamental Metrics

Financial Performance
Metric
NGNE
CIX
Price
$20.59
$21.60
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$38.50
N/A
AVG Volume (30 Days)
234.3K
4.8K
Earning Date
11-13-2025
11-05-2025
Dividend Yield
N/A
10.15%
EPS Growth
N/A
2.86
EPS
N/A
1.57
Revenue
N/A
$159,004,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.82
Revenue Growth
N/A
5.52
52 Week Low
$6.88
$17.89
52 Week High
$37.27
$32.34

Technical Indicators

Market Signals
Indicator
NGNE
CIX
Relative Strength Index (RSI) 41.09 40.17
Support Level $19.23 $21.50
Resistance Level $23.00 $22.31
Average True Range (ATR) 1.59 0.40
MACD 0.00 -0.04
Stochastic Oscillator 39.65 7.75

Price Performance

Historical Comparison
NGNE
CIX

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.

Share on Social Networks: